Trials & Filings
Related Searches:
Filter by:
March 29, 2007
Hollis-Eden Pharmaceuticals, Inc. filed an IND application with FDA to begin a Phase I trial with its next-generation drug candidate, HE3286, for the treatment of metabolic disorders, which include diabetes, obesity and dyslipidemia. The trial progra…
Read More »
March 27, 2007
Barrier Therapeutics achieved positive results from its Phase IIb dose ranging study for its antifungal candidate pramiconazole (previously known as Azoline). Pramiconazole met the primary endpoint of effectively treating tinea (pityriasis) versicolo…
Read More »
March 26, 2007
The European Commission has approved Merck's Januvia, a once-daily oral treatment for patients with type 2 diabetes. Januvia is the first medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance…
Read More »
March 21, 2007
Emergent BioSolutions, Inc. has submitted an IND application with the FDA for its Anthrax Immune Globulin (AIG) product candidate. AIG is a therapeutic treatment for patients with symptoms of anthrax disease resulting from the release of anthrax toxi…
Read More »
March 20, 2007
AtheroGenics, Inc.'s AGI-1067, which is being developed in partnership with AstraZeneca, did not meet its primary endpoint in a Phase III trial. AGI-1067 is aimed at reducing the buildup of plaque inside arteries by addressing the inflammation behind…
Read More »
March 16, 2007
Exelixis has submitted an IND application to the FDA for XL147, a novel anticancer compound. XL147 is an orally available small molecule inhibitor of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting…
Read More »
March 14, 2007
GlaxoSmithKline has received approval from the FDA for Tykerb in combination with Xeloda for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycl…
Read More »
March 9, 2007
Roche has filed a sNDA with the FDA to market Tamiflu capsules in pediatric doses of 30 mg and 45 mg. Tamiflu, which is indicated for the prevention and treatment of flu types A and B in patients one year and older, is currently available in a 75 mg…
Read More »
March 8, 2007
Pfizer has received FDA approval for Lipitor Tablets for five new indications: to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients wi…
Read More »
March 7, 2007
Novartis AG has received approval from the FDA for Tekturna, the first new class of drug in more than a decade approved for treating high blood pressure. The drug acts by inhibiting renin, an enzyme secreted primarily by the kidneys that raises blood…
Read More »
March 7, 2007
Wyeth Pharmaceuticals and Progenics Pharmaceuticals will begin clinical testing of a new formulation of oral methylnaltrexone for the treatment of opioid-induced constipation. Preliminary results from the Phase II trial, conducted by Wyeth, showed th…
Read More »
March 6, 2007
InterMune, Inc. has discontinued the Phase III INSPIRE trial evaluating Actimmune in patients with idiopathic pulmonary fibrosis (IPF) based on the recommendation of an independent data monitoring committee (DMC). Interim analysis included a total of…
Read More »
March 5, 2007
Memory Pharmaceuticals' Phase IIa study of MEM 1003 in acute mania in bipolar disorder, based on primary and secondary outcome measures in the trial, did not prove effective.
The multi-center, double-blind, randomized, placebo-controlled study e…
Read More »
March 2, 2007
Astellas Pharma U.S., Inc. received approval from the FDA for Vaprisol, a receptor antagonist for the treatment of hypervolemic hyponatremia in hospitalized patients. Vaprisol, discovered and developed by Astellas, is the first drug specifically ind…
Read More »
February 28, 2007
Abbott received approval from the FDA to market Humira as a treatment for reducing symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to convention…
Read More »
